🔓 Unlock the full profile of Ravinder Verma (Nextrove), including verified contact details, financial insights, and professional associations.

See Ravinder Verma Full Profile

Below are the ✅ Verified Contact Details to help you connect directly:

Email: rav*****@nex******.com

Mobile: 66929*****

Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)

Key Insights You Should Know About This Individual

  • Ravinder Verma co-founded Nextrove, LLC in January 2022, taking on the role of Vice President and impacting the company's strategic direction and growth.
  • Before Nextrove, Ravinder Verma was a co-founder of SoniBros FX Studio starting in October 2009, contributing to the establishment and development of the studio's creative endeavors.
  • Ravinder Verma served as Head of Product Development at Nextrove from July 2019 until January 2022, overseeing the development of innovative products and services that shaped the company's offerings.
  • Previously, from February 2017 to October 2018, in a managerial role at HighPoint Solutions, Ravinder Verma navigated challenges in team leadership and project management, providing valuable contributions to client solutions.
  • Ravinder Verma held the position of Development Manager at November Research Group from January 2016 to February 2017, driving product development and managing a team of developers.
  • Prior roles include Lead Developer and Senior Principal Consultant at November Research Group, where Ravinder Verma contributed to significant projects from January 2013 to December 2015, enhancing technical capabilities and project delivery.
  • Ravinder Verma worked as a Technical Lead at HCL Technologies from August 2010 to August 2012, focusing on project implementation and technical oversight, ensuring high standards in product delivery.
  • Earlier career experiences include positions at Oracle India Pvt. Ltd., Relsys India, Mindfire Solutions, and SunBeam Software Inc., where foundational skills in software engineering and project management were developed.